Furthermore, sacituzumab govitecan demonstrated efficacy for HR-positive HER2-negative breast cancer in the phase III TROPiCS-02 trial [28], where sacituzumab govitecan was compared with physician’s choice chemotherapy in patients with endocrine-resistant, chemotherapy-treated HR+ HER2-negative advanced breast cancer. This evidence concerns the gene ERBB2 and breast cancer.